Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2012, Article ID 607260, 6 pages
http://dx.doi.org/10.1155/2012/607260
Clinical Study

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma

Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Policlinico, Piazza Giulio Cesare 11, I-70124 Bari, Italy

Received 2 December 2011; Accepted 6 April 2012

Academic Editor: Stefan Arnhold

Copyright © 2012 Roberto Ria et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Cunningham, L. Paz-Ares, S. Milan et al., “High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma,” Journal of Clinical Oncology, vol. 12, no. 4, pp. 759–763, 1994. View at Google Scholar · View at Scopus
  2. W. I. Bensinger, S. D. Rowley, T. Demirer et al., “High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1447–1456, 1996. View at Google Scholar · View at Scopus
  3. J. P. Fermand, P. Ravaud, S. Chevret et al., “High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients,” Stem Cells, vol. 13, no. 2, pp. 156–159, 1995. View at Google Scholar · View at Scopus
  4. K. C. Anderson, J. Andersen, R. Soiffer et al., “Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma,” Blood, vol. 82, no. 8, pp. 2568–2576, 1993. View at Google Scholar · View at Scopus
  5. G. Tricot, S. Jagannath, D. Vesole et al., “Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients,” Blood, vol. 85, no. 2, pp. 588–596, 1995. View at Google Scholar · View at Scopus
  6. S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp, “Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. V. Rajkumar, S. Hayman, M. A. Gertz et al., “Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4319–4323, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Weber, K. Rankin, M. Gavino, K. Delasalle, and R. Alexanian, “Thalidomide alone or with dexamethasone for previously untreated multiple myeloma,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 16–19, 2003. View at Google Scholar · View at Scopus
  9. N. Raje and K. Anderson, “Thalidomide—a revival story,” The New England Journal of Medicine, vol. 341, no. 21, pp. 1606–1609, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. A. De Luisi, A. Ferrucci, A. M. L. Coluccia et al., “Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma,” Clinical Cancer Research, vol. 17, no. 7, pp. 1935–1946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Singhal, J. Mehta, R. Desikan et al., “Antitumor activity of thalidomide in refractory multiple myeloma,” The New England Journal of Medicine, vol. 341, pp. 1565–1571, 1999. View at Google Scholar
  12. H. Quach, D. Ritchie, A. K. Stewart et al., “Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma,” Leukemia, vol. 24, no. 1, pp. 22–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Hideshima and K. C. Anderson, “Molecular mechanisms of novel therapeutic approaches for multiple myeloma,” Nature Reviews Cancer, vol. 2, no. 12, pp. 927–937, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Hideshima, D. Chauhan, P. Richardson et al., “NF-?B as a therapeutic target in multiple myeloma,” The Journal of Biological Chemistry, vol. 277, no. 19, pp. 16639–16647, 2002. View at Google Scholar
  15. T. Hideshima, P. Richardson, D. Chauhan et al., “The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells,” Cancer Research, vol. 61, no. 7, pp. 3071–3076, 2001. View at Google Scholar · View at Scopus
  16. N. Mitsiades, C. S. Mitsiades, V. Poulaki et al., “Molecular sequelae of proteasome inhibition in human multiple myeloma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14374–14379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Demirer, C. Dean Buckner, and W. I. Bensinger, “Optimization of peripheral blood stem cell mobilization,” Stem Cells, vol. 14, no. 1, pp. 106–116, 1996. View at Google Scholar · View at Scopus
  18. M. Mohty, R. F. Duarte, S. Croockewit, K. Hübel, G. Kvalheim, and N. Russell, “The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation,” Leukemia, vol. 25, no. 1, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Zangari, E. Anaissie, B. Barlogie et al., “Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy,” Blood, vol. 98, no. 5, pp. 1614–1615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Palumbo, S. V. Rajkumar, M. A. Dimopoulos et al., “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma,” Leukemia, vol. 22, no. 2, pp. 414–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. C. Kane, P. F. Bross, A. T. Farrell, and R. Pazdur, “Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy,” Oncologist, vol. 8, no. 6, pp. 508–513, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Cavo, E. Zamagni, P. Tosi et al., “Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma,” Blood, vol. 106, no. 1, pp. 35–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Cavo, P. Tacchetti, F. Patriarca et al., “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” The Lancet, vol. 376, no. 9758, pp. 2075–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Jagannath, B. G. M. Durie, J. Wolf et al., “Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma,” British Journal of Haematology, vol. 129, no. 6, pp. 776–783, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Popat, H. E. Oakervee, S. Hallam et al., “Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up,” British Journal of Haematology, vol. 141, no. 4, pp. 512–516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. V. Rajkumar, S. Jacobus, N. S. Callander et al., “Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial,” The Lancet Oncology, vol. 11, no. 1, pp. 29–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. T. Vogl, S. V. Liu, E. A. Chong et al., “Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support,” American Journal of Hematology, vol. 82, no. 12, pp. 1071–1075, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp, “Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Ria, T. Gasparre, G. Mangialardi et al., “Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs,” Bone Marrow Transplantation, vol. 45, no. 2, pp. 277–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. G. M. Keating, “Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma,” Drugs, vol. 71, no. 12, pp. 1623–1647, 2011. View at Google Scholar
  31. B. G. M. Durie, J. L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Cavo, S. V. Rajkumar, A. Palumbo et al., “International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation,” Blood, vol. 117, no. 23, pp. 6063–6073, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. G. Richardson, P. Sonneveld, M. W. Schuster et al., “Bortezomib or high-dose dexamethasone for relapsed multiple myeloma,” The New England Journal of Medicine, vol. 352, no. 24, pp. 2487–2498, 2005. View at Google Scholar
  34. M. Cavo, P. Tosi, E. Zamagni et al., “Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study,” Journal of Clinical Oncology, vol. 25, no. 17, pp. 2434–2441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Barlogie, G. Tricot, E. Anaissie et al., “Thalidomide and hematopoietic-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 354, no. 10, pp. 1021–1030, 2006. View at Google Scholar
  36. J. L. Harousseau, M. Attal, H. Avet-Loiseau et al., “Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4621–4629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. P. G. Richardson, E. Weller, S. Lonial et al., “Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma,” Blood, vol. 116, no. 5, pp. 679–686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Palumbo, S. V. Rajkumar, M. A. Dimopoulos et al., “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma,” Leukemia, vol. 22, no. 2, pp. 414–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Kumar, A. Dispenzieri, M. Q. Lacy et al., “Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma,” Leukemia, vol. 21, no. 9, pp. 2035–2042, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. A. Sekeres, J. P. Maciejewski, A. A. N. Giagounidis et al., “Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5943–5949, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. Zonder, B. Barlogie, B. G. M. Durie, J. McCoy, J. Crowley, and M. A. Hussein, “Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis,” Blood, vol. 108, no. 1, article 403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Kumar, S. Giralt, E. A. Stadtmauer et al., “Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens,” Blood, vol. 114, no. 9, pp. 1729–1735, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Mark, J. Stern, J. R. Furst et al., “Stem cell mobilization with Cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 14, no. 7, pp. 795–798, 2008. View at Publisher · View at Google Scholar · View at Scopus